Contineum Therapeutics, Inc.
CTNM
$3.91
-$0.08-2.01%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 50.00M | 50.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 50.00M | 50.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | 0.00 | 50.00M | 50.00M |
| SG&A Expenses | 13.20M | 10.65M | 8.95M | 7.93M | 7.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.90M | 43.52M | 38.62M | 38.74M | 33.92M |
| Operating Income | -50.90M | -43.52M | -38.62M | 11.26M | 16.08M |
| Income Before Tax | -42.26M | -35.62M | -31.73M | 19.58M | 23.17M |
| Income Tax Expenses | -- | -161.00K | -279.00K | 450.00K | 450.00K |
| Earnings from Continuing Operations | -42.26 | -35.46 | -31.45 | 19.13 | 22.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.26M | -35.46M | -31.45M | 19.13M | 22.72M |
| EBIT | -50.90M | -43.52M | -38.62M | 11.26M | 16.08M |
| EBITDA | -50.64M | -43.30M | -38.42M | 11.45M | 16.27M |
| EPS Basic | -4.90 | -4.85 | -7.14 | -1.98 | 1.42 |
| Normalized Basic EPS | -3.06 | -4.83 | -6.29 | 5.48 | 6.38 |
| EPS Diluted | -4.91 | -4.85 | -7.14 | -4.96 | -1.56 |
| Normalized Diluted EPS | -3.06 | -4.83 | -6.29 | -0.17 | 0.72 |
| Average Basic Shares Outstanding | 77.27M | 53.80M | 30.39M | 9.33M | 9.24M |
| Average Diluted Shares Outstanding | 77.27M | 53.80M | 30.39M | 11.53M | 11.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |